Auspex Pharmaceuticals (ASPX) Posts Wider Q1 Loss

Auspex Pharmaceuticals (NASDAQ: ASPX) reported Q1 EPS of ($0.81), $0.42 worse than the analyst estimate of ($0.39). At March 31, 2014, Auspex had cash and marketable securities balance of $119.8 million and had 23,610,007 shares outstanding.

"The first quarter of 2014 has been an exciting time of growth and activity for Auspex as we are advancing our lead program SD-809 (dutetrabenazine) through the Phase 3 pivotal study in chorea associated with Huntington's disease (HD) and towards commercialization," said Pratik Shah, Ph.D., President and CEO of Auspex. "Our successful initial public offering in February has allowed us to execute on our strategy of developing SD-809 for HD and other debilitating hyperkinetic movement disorders such as tardive dyskinesia and Tourette syndrome. In addition, we are advancing our second program, SD-560, towards clinical development for the potential treatment of idiopathic pulmonary fibrosis and other fibrotic conditions."

For earnings history and earnings-related data on (not found) (ASPX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery